Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs
Abstract Oncolytic virotherapy is an emerging strategy that uses replication-competent viruses to kill tumor cells. We have reported the oncolytic effects of TG6002, a recombinant oncolytic vaccinia virus, in preclinical human xenograft models and canine tumor explants. To assess the safety, biodist...
Guardado en:
Autores principales: | Jérémy Béguin, Murielle Gantzer, Isabelle Farine, Johann Foloppe, Bernard Klonjkowski, Christelle Maurey, Éric Quéméneur, Philippe Erbs |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/68a68d93323c4c66a8300f3d5dd7b61e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Yi Wang, et al.
Publicado: (2021) -
Stability and ocular biodistribution of topically administered PLGA nanoparticles
por: Sean Swetledge, et al.
Publicado: (2021) -
IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
por: Xiaoyan Zhang, et al.
Publicado: (2021) -
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
por: Zuqiang Liu, et al.
Publicado: (2017) -
Correction: IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
Publicado: (2021)